17 results
8-K
EX-10.1
INM
InMed Pharmaceuticals Inc
19 Jul 22
InMed Announces Appointment of Chief Operating Officer
7:43pm
of $15,000 will be paid in the form of a retention bonus as outlined in section 2(b) below.
(ii)
The Executive’s Base Salary will be reviewed annually … % in the event of a reduction of salary under this section 2(a)(iii).
Retention Bonuses. The Executive will be provided with a retention bonus in the amount
8-K/A
yutbdvqi
16 Nov 21
Regulation FD Disclosure
5:29pm
8-K
EX-99.1
sr92jo5xrco
10 Nov 21
InMed Pharmaceuticals Reports First Quarter Fiscal 2022 Financial Results and Provides Business Update
1:08pm
DEF 14A
3rp 4kz47wj
28 Oct 21
Definitive proxy
3:07pm
8-K
EX-2.1
hpd6eqx m0lcbidth0j
13 Oct 21
InMed Pharmaceuticals Completes Acquisition of BayMedica Creating a Market Leader in the Manufacturing of Rare Cannabinoids
5:00pm
10-K
EX-2.1
yh7i598taoql3m6z4v
24 Sep 21
Annual report
7:31am
10-Q
EX-3.1
r9hxu0qqp
17 Dec 20
Quarterly report
12:00am
S-1
EX-3.1
c7gi g86qk4kq1z29
19 Jun 20
IPO registration
4:59pm
S-1
EX-10.9
gs4iylj8szwsqfbo15
19 Jun 20
IPO registration
4:59pm
DRS/A
EX-10.9
m9db6
27 May 20
Draft registration statement (amended)
12:00am
DRS/A
EX-3.1
lyk8gs0smq
27 May 20
Draft registration statement (amended)
12:00am
DRS
EX-3.1
b2lvy
13 Apr 20
Draft registration statement
12:00am
DRS
EX-10.9
otqde2hx8xmmr8dcsmh
13 Apr 20
Draft registration statement
12:00am
- Prev
- 1
- Next